Home Cart Sign in  
Chemical Structure| 1430844-80-6 Chemical Structure| 1430844-80-6

Structure of A-1331852
CAS No.: 1430844-80-6

Chemical Structure| 1430844-80-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

A1331852 is a potent and selective BCL-XL inhibitor and may be useful in the treatment of cancer, immune and autoimmune diseases.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of A-1331852

CAS No. :1430844-80-6
Formula : C38H38N6O3S
M.W : 658.81
SMILES Code : O=C(O)C1=NC(N2CC3=C(C=CC=C3C(NC4=NC5=CC=CC=C5S4)=O)CC2)=CC=C1C6=C(C)N(CC78CC9CC(C8)CC(C9)C7)N=C6
MDL No. :MFCD30532662
InChI Key :QCQQONWEDCOTBV-UHFFFAOYSA-N
Pubchem ID :71565985

Safety of A-1331852

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Bcl-xL

    Bcl-xL, Ki:<0.01 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Meljuso cells 250 nM 2 weeks Evaluate the effect of A-1331852 on Meljuso cells, results showed MCL1 as a top sensitizer gene Nat Commun. 2020 Feb 6;11(1):752.
OVCAR8 cells 250 nM 2 weeks Evaluate the effect of A-1331852 on OVCAR8 cells, results showed MCL1 as a top sensitizer gene Nat Commun. 2020 Feb 6;11(1):752.
H2030 cells 1 μM 72 h To evaluate the effect of A-1331852 on H2030 cells, results showed that pre-treatment increased sensitivity to MEK + MCL-1 inhibition. Cancer Discov. 2018 Dec;8(12):1598-1613.
H1734 cells 1 μM 72 h To evaluate the effect of A-1331852 on H1734 cells, results showed that pre-treatment increased sensitivity to MEK + MCL-1 inhibition. Cancer Discov. 2018 Dec;8(12):1598-1613.
CAKI-2 10 nM 16 h To evaluate the apoptotic induction effect of A-1331852 on CAKI-2 cells, results showed a significant increase in apoptotic cell population Clin Cancer Res. 2022 Nov 1;28(21):4689-4701.
A-498 100 nM 36 h To evaluate the apoptotic induction effect of A-1331852 on A-498 cells, results showed a significant increase in apoptotic cell population Clin Cancer Res. 2022 Nov 1;28(21):4689-4701.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Tuberculosis model Oral 25 mg/kg Once daily for 2 weeks To evaluate the therapeutic effect of A-1331852 in a tuberculosis mouse model, results showed no significant difference in bacterial numbers in the lungs and spleens between A-1331852-treated and vehicle-treated mice Front Immunol. 2018 May 28;9:1178
Athymic nude mice JH4.3 xenograft model Oral 25 mg/kg Once daily for 35 days To evaluate the antitumor efficacy of A-1331852 in the JH4.3 xenograft model. Results showed that A-1331852 significantly inhibited tumor growth, with a significant reduction in tumor volume compared to the control group. Nat Commun. 2018 Aug 29;9(1):3513
Mice H2030 sub-cutaneous xenograft model Oral 25 mg/kg Pre-treatment for 4 days, followed by a 3-day drug holiday, then 5 days of MEK + MCL-1 inhibitor treatment To evaluate the effect of A-1331852 pre-treatment on H2030 xenograft tumors, results showed that pre-treatment increased sensitivity to MEK + MCL-1 inhibition and led to tumor regression. Cancer Discov. 2018 Dec;8(12):1598-1613.
Mice CCl4-induced liver fibrosis model Oral 20 mg/kg Every other day for 2 weeks To study the effects of A-1331852 on CCl4-induced liver fibrosis, results showed that A-1331852 exacerbated liver injury and fibrosis. Hepatology. 2023 Jun 1;77(6):1998-2015
NCRnu/nu mice Subcutaneous tumor model Oral 25 mg/kg Twice daily for 4 weeks To evaluate the inhibitory effect of A-1331852 on subcutaneous tumor growth, results showed significant reduction in tumor volume and increased apoptotic cells Clin Cancer Res. 2022 Nov 1;28(21):4689-4701.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.52mL

0.30mL

0.15mL

7.59mL

1.52mL

0.76mL

15.18mL

3.04mL

1.52mL

References

 

Historical Records

Categories